Losartan for Sickle Cell Disease
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial is testing losartan, a blood pressure medication, in patients aged 6 and older with Sickle Cell Disease. The goal is to see if it can safely reduce fluid buildup in the body over time.
Are You a Good Fit for This Trial?
This trial is for patients 6 years or older with Sickle Cell Disease (SCD), specifically HbSS or Sbeta0-thalassemia. They must be able to undergo heart imaging without sedation and have been on a stable dose of certain SCD therapies for 3 months. Excluded are those on chronic transfusion therapy, with severe kidney issues, pregnant women not using contraception, and others listed in the exclusion criteria.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive oral losartan daily for 12 months to assess its efficacy in stabilizing or decreasing extracellular volume fraction (ECV) in Sickle Cell Disease
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessments of myocardial fibrosis and exercise capacity
What Are the Treatments Tested in This Trial?
Interventions
- Losartan
Losartan is already approved in United States, European Union, Canada for the following indications:
Find a Clinic Near You
Who Is Running the Clinical Trial?
Children's Hospital Medical Center, Cincinnati
Lead Sponsor